Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Endeavour Silver Corp (EXK) Price & Performance

AbbVie IncTrade
Endeavour Silver CorpTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Endeavour Silver Corp — how do they compare? AbbVie Inc trades at $249.55 (market cap $438.19B), while Endeavour Silver Corp trades at $10.8 (market cap $3.03B). The key difference: AbbVie Inc is far larger — about 144.6× Endeavour Silver Corp's market cap, and AbbVie Inc pays a 2.79% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.

ABBVEXK
Market Cap
$438.19B$3.03B
Sector
HealthBasic Materials
52-Week High
$263.58$14.12
52-Week Low
$197.38$5.31
Enterprise Value
$502.45B$3.04B
Dividend Yield
2.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Endeavour Silver Corp

EXK is trading at $9.54, up 8.04% today, with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with Q2 2026 earnings matching estimates and revenue growth from $468M in 2025 to $737M projected for 2026. Recent news highlights a $25M credit facility and operational expansion at Terronera mine.

Outlook remains positive with analyst consensus price target of $15.50 (62% upside), though risks include volatile earnings history and elevated P/E ratio of 51.2. The stock offers growth potential through silver production expansion but faces commodity price sensitivity and execution risks in mine development.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Endeavour Silver Corp

Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.

Read more on EXK